

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (currently amended) The ~~formulation of claim 1, comprising~~ method of claim 13, wherein the formulation comprises the ganglioside GD3.

Claim 3 (currently amended) The ~~formulation of claim 1, comprising~~ method of claim 13, wherein the formulation comprises the ganglioside GM3.

Claim 4 (currently amended) The ~~formulation of claim 1, method of claim 13,~~ wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight.

Claim 5 (currently amended) The ~~formulation of claim 1, method of claim 13,~~ wherein the percentage of GM3 in the formulation, expressed as a function of total gangliosides is at least 50% by weight.

Claim 6 (currently amended) The ~~formulation of claim 1, comprising~~ method of claim 13, wherein the formulation comprises 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.

Claim 7 (currently amended) The ~~formulation of claim 1 comprising~~ method of claim 13, wherein the formulation comprises about 80% GD3 and about 5% GM3 by weight based on total gangliosides.

Claim 8 (currently amended) The ~~formulation of claim 1,~~ method of claim 13, wherein mediating inflammation comprises mediating inflammation of the intestine, retina, or neuronal tissue.

Claim 9 (currently amended) The ~~formulation of claim 1,~~ method of claim 13, wherein mediating inflammation comprises preventing or treating an inflammatory disease.

Claim 10 (currently amended) The ~~formulation of claim 9,~~ method of claim 9, wherein said inflammatory disease is selected from the group consisting of inflammatory bowel disorders, disorders arising from allergic responses, and diseases involving epithelial surface responses.

Claim 11 (currently amended) The ~~formulation of claim 1,~~ method of claim 13, wherein the formulation is in the form of a supplemented liquid or food.

Claim 12 (currently amended) The ~~formulation of~~ method of claim 11, wherein said supplemented liquid or food comprises infant formula or infant foods.

Claim 13 (currently amended) A method for mediating inflammation in a subject in need thereof comprising the step of providing the ~~formulation of claim 1~~ a formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, and GD1b, to said subject for oral consumption.

Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (currently amended) ~~The formulation of claim 16, comprising~~ method of claim 25, wherein the formulation comprises the ganglioside GD3 or GM3.

Claim 18 (canceled)

Claim 19 (currently amended) ~~The formulation of claim 16,~~ method of claim 25, wherein the percentage of GD3 in the formulation, expressed as a function of total gangliosides is at least 50% by weight.

Claim 20 (currently amended) ~~The formulation of claim 16,~~ method of claim 25, wherein the percentage of GM3 in the formulation, expressed as a function of total gangliosides is at least 50% by weight.

Claim 21 (currently amended) ~~The formulation of claim 16, comprising~~ method of claim 25, wherein the formulation comprises 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.

Claim 22 (currently amended) ~~The formulation of claim 16, comprising~~ method of claim 25, wherein the formulation comprises about 80% GD3 and about 5% GM3 by weight based on total gangliosides.

Claim 23 (currently amended) ~~The formulation of claim 16,~~ method of claim 25, wherein the formulation is in the form of a supplemented liquid or food.

Claim 24 (currently amended) ~~The formulation~~ method of claim 23, wherein said supplemented liquid or food comprises infant formula or infant foods.

Claim 25 (currently amended) A method for reducing plasma cholesterol level in a subject in need thereof comprising the step of providing ~~the formulation of claim 16~~ a

formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, and GD1b, to said subject for oral consumption.

Claim 26 (canceled)

Claim 27 (canceled)